GC Green Cross flu treatment 'Peramiflu' receives approval for administration to infants and young children

GC Green Cross flu treatment 'Peramiflu' (Photo by GC Green Cross)

[Asia Economy Reporter Lee Chun-hee] GC Green Cross's flu treatment 'Peramiflu' has received approval for administration to infants and toddlers.

GC Green Cross announced on the 5th that it obtained approval from the Ministry of Food and Drug Safety for the intravenous flu treatment 'Peramiflu' to be administered to infants aged 6 months to under 2 years. This is the first time an injectable flu treatment has been approved for this age group in South Korea.

Peramiflu, launched in 2010, is an antiviral drug for treating influenza A and B virus infections. Unlike oral treatments that require a total of 10 doses over 5 days, it can cure the flu with a single injection.

A Green Cross official said, "It is significant in that it provides a new treatment option for young patients who have difficulty with oral administration," and added, "It will continue to play a leading role in the flu treatment market."

Meanwhile, this approval followed the expanded age use approval in the United States, where Biocrest, the raw material supplier of Peramiflu, demonstrated safety and efficacy to the U.S. Food and Drug Administration (FDA), leading to consecutive approvals domestically.

This content was produced with the assistance of AI translation services.